Study Number:	I10482
Study Gender:	Female
PWG Approval Date:	See web page for date of PWG Approval
Version:	v1.3.2
Stat Version:	v2.7.2A

Female: SRBC

	Treatment Groups (ppm)						
	0	**313**	**625**	**1250**	**2500**	**5000**	**50 mg/kg CPS**
Disposition Summary							
Animals Initially In Study	**8**	**8**	**8**	**8**	**8**	**8**	**8**
Censored							
Early Deaths							
Survivors							
Scheduled Sacrifice, Terminal	**8**	**8**	**8**	**8**	**8**	**8**	**8**
Number of Animals Examined	**8**	**8**	**8**	**8**	**8**	**7**	**8**
ALIMENTARY SYSTEM							
None							
CARDIOVASCULAR SYSTEM							
None							
ENDOCRINE SYSTEM							
None							
GENERAL BODY SYSTEM							
None							
GENITAL SYSTEM							
None							
HEMATOLYMPHOID SYSTEM							
SPLEEN	(0)	(0)	(0)	(0)	(0)	(0)	(8)
SMALL; MARKED	0						8 (100.0%) **
THYMUS	(0)	(0)	(0)	(0)	(0)	(0)	(8)
SMALL; MARKED	0						8 (100.0%) **
INTEGUMENTARY SYSTEM							
None							

Female: SRBC

	Treatment Groups (ppm)						
	0	**313**	**625**	**1250**	**2500**	**5000**	**50 mg/kg CPS**
MUSCULOSKELETAL SYSTEM							
None							
NERVOUS SYSTEM							
None							
RESPIRATORY SYSTEM							
None							
SPECIAL SENSES SYSTEM							
None							
URINARY SYSTEM							
None							

Female: KLH

	Treatment Groups (ppm)						
	0	**313**	**625**	**1250**	**2500**	**5000**	**50 mg/kg CPS**
Disposition Summary							
Animals Initially In Study	**8**	**8**	**8**	**8**	**8**	**8**	**8**
Censored							
Early Deaths							
Survivors							
Scheduled Sacrifice, Terminal	**8**	**8**	**8**	**8**	**8**	**8**	**8**
Number of Animals Examined	**8**	**8**	**8**	**8**	**8**	**7**	**8**
ALIMENTARY SYSTEM							
None							
CARDIOVASCULAR SYSTEM							
None							
ENDOCRINE SYSTEM							
None							
GENERAL BODY SYSTEM							
None							
GENITAL SYSTEM							
None							
HEMATOLYMPHOID SYSTEM							
None							
INTEGUMENTARY SYSTEM							
None							
MUSCULOSKELETAL SYSTEM							
None							

Female: KLH

	Treatment Groups (ppm)						
	0	**313**	**625**	**1250**	**2500**	**5000**	**50 mg/kg CPS**
NERVOUS SYSTEM							
None							
RESPIRATORY SYSTEM							
None							
SPECIAL SENSES SYSTEM							
None							
URINARY SYSTEM							
None							

Female: Immunophenotyping

	Treatment Groups (ppm)						
	0	**313**	**625**	**1250**	**2500**	**5000**	**50 mg/kg CPS**
Disposition Summary							
Animals Initially In Study	**8**	**8**	**8**	**8**	**8**	**8**	**8**
Censored							
Early Deaths							
Survivors							
Scheduled Sacrifice, Terminal	**8**	**8**	**8**	**8**	**8**	**8**	**8**
Number of Animals Examined	**8**	**8**	**8**	**8**	**8**	**8**	**8**
ALIMENTARY SYSTEM							
None							
CARDIOVASCULAR SYSTEM							
None							
ENDOCRINE SYSTEM							
None							
GENERAL BODY SYSTEM							
None							
GENITAL SYSTEM							
None							
HEMATOLYMPHOID SYSTEM							
SPLEEN	(0)	(0)	(0)	(0)	(0)	(0)	(8)
SMALL; MARKED	0						8 (100.0%) **
THYMUS	(0)	(0)	(0)	(0)	(0)	(0)	(8)
SMALL; MARKED	0						8 (100.0%) **
INTEGUMENTARY SYSTEM							
None							

Female: Immunophenotyping

	Treatment Groups (ppm)						
	0	**313**	**625**	**1250**	**2500**	**5000**	**50 mg/kg CPS**
MUSCULOSKELETAL SYSTEM							
None							
NERVOUS SYSTEM							
None							
RESPIRATORY SYSTEM							
None							
SPECIAL SENSES SYSTEM							
None							
URINARY SYSTEM							
None							

Female: CTL

	Treatment Groups (ppm)						
	0	**313**	**625**	**1250**	**2500**	**5000**	**50 mg/kg CPS**
Disposition Summary							
Animals Initially In Study	**8**	**8**	**8**	**8**	**8**	**8**	**8**
Censored							
Early Deaths							
Sacrificed, Moribund							**1**
Survivors							
Scheduled Sacrifice, Terminal	**8**	**8**	**8**	**8**	**8**	**8**	**7**
Number of Animals Examined							
ALIMENTARY SYSTEM							
None							
CARDIOVASCULAR SYSTEM							
None							
ENDOCRINE SYSTEM							
None							
GENERAL BODY SYSTEM							
None							
GENITAL SYSTEM							
None							
HEMATOLYMPHOID SYSTEM							
None							
INTEGUMENTARY SYSTEM							
None							

Female: CTL

	Treatment Groups (ppm)						
	0	**313**	**625**	**1250**	**2500**	**5000**	**50 mg/kg CPS**
MUSCULOSKELETAL SYSTEM							
None							
NERVOUS SYSTEM							
None							
RESPIRATORY SYSTEM							
None							
SPECIAL SENSES SYSTEM							
None							
URINARY SYSTEM							
None							

Female: Immunopath

	Treatment Groups (ppm)						
	0	**313**	**625**	**1250**	**2500**	**5000**	**50 mg/kg CPS**
Disposition Summary							
Animals Initially In Study	**8**	**8**	**8**	**8**	**8**	**8**	**8**
Censored							
Early Deaths							
Survivors							
Scheduled Sacrifice, Terminal	**8**	**8**	**8**	**8**	**8**	**8**	**8**
Number of Animals Examined	**8**	**8**	**8**	**8**	**8**	**8**	**8**
ALIMENTARY SYSTEM							
LIVER	(8)	(8)	(8)	(8)	(8)	(8)	(8)
MALFORMATION			1 (12.5%)				
SMALL; MILD							1 (12.5%)
CARDIOVASCULAR SYSTEM							
None							
ENDOCRINE SYSTEM							
ADRENAL GLAND, RIGHT	(8)	(8)	(8)	(8)	(8)	(8)	(0)
SMALL; MILD			1 (12.5%)				
SMALL; MODERATE			1 (12.5%)				
GENERAL BODY SYSTEM							
None							
GENITAL SYSTEM							
None							

Female: Immunopath

	Treatment Groups (ppm)						
	0	**313**	**625**	**1250**	**2500**	**5000**	**50 mg/kg CPS**
HEMATOLYMPHOID SYSTEM							
SPLEEN	(8)	(8)	(8)	(8)	(8)	(8)	(8)
DISCOLORATION; BLACK			1 (12.5%)			1 (12.5%)	
SMALL; MARKED	0						4 (50.0%) *
SMALL; MILD	1 (12.5%)			1 (12.5%)	1 (12.5%)	1 (12.5%)	2 (25.0%)
SMALL; MODERATE			1 (12.5%)				1 (12.5%)
THYMUS	(8)	(8)	(8)	(8)	(8)	(8)	(8)
SMALL; MARKED	0						7 (87.5%) **
SMALL; MILD			1 (12.5%)	1 (12.5%)		1 (12.5%)	
SMALL; MODERATE	1 (12.5%)				2 (25.0%)	1 (12.5%)	
INTEGUMENTARY SYSTEM							
None							
MUSCULOSKELETAL SYSTEM							
None							
NERVOUS SYSTEM							
None							
RESPIRATORY SYSTEM							
None							
SPECIAL SENSES SYSTEM							
None							
URINARY SYSTEM							
None							

LEGEND

Censored animals are scheduled for sacrifice prior to the end of the study. The censored animals are included in the pathology data.

Number of animals examined for each tissue shown in parentheses. If none of the animals examined have the specific lesion then there is a blank for that dose group for that specific lesion. The exception to this is if statistical significance is found for a lesion and the control group has no animals with the lesion then a 0 is included for the control group on the table for that lesion.

Number (percent) of animals affected given for each observation

Statistical analysis performed by Cochran-Armitage (trend) and Fisher Exact (pairwise) one-sided tests.

Statistical analysis for the positive control group compared to the vehicle control group was performed using the Fisher Exact test.

Statistical significance for the control group indicates a significant trend test

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group

* Statistically significant at P <= 0.05

** Statistically significant at P <= 0.01

CPS = Cyclophosphamide

** END OF REPORT **